Trial Profile
To investigate peroxisome proliferator-activated receptor (PPAR) γ and CD36 receptor gene expression in blood leukocytes of multiple sclerosis patients treated with fingolimod.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Nov 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 22 Nov 2017 New trial record
- 28 Oct 2017 Results assessing peroxisome proliferator-activated receptor (PPAR) and CD36 receptor gene expression in blood leukocytes of multiple sclerosis patients treated with fingolimod, were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.